DGX News and Press, Quest Diagnostics Incorporated From 01/09/24

Goal to combine Ultima’s highly sensitive, low-cost technology with Quest’s oncology expertise and national scale in order to improve patient access, affordability and outcomes Ultima Genomics , a developer of a revolutionary new ultra-high throughput sequencing archit...

Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System PR Newswire Transaction to broaden access to innovative, quality diagnostic information services for providers and patients SECAUCUS, N.J. , Jan. 8, 2024 ...

Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC PR Newswire BALTIMORE , Jan. 8, 2024 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX)...

2024-01-08 03:40:52 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...

NORTHAMPTON, MA / ACCESSWIRE / January 4, 2024 / Quest Diagnostics recently provided no-cost Blueprint for Wellness® testing to more than 100 local community members who attended a wellness day in the Mississippi Delta region. The ninth annual I-HEAL Community Wellness Day, hosted by Quest ...

Quest Diagnostics to Speak at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire SECAUCUS, N.J. , Dec. 21, 2023 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the nation's leading provider of diagnostic information services, announced that...

Quest Diagnostics Names Yuri A. Fesko, M.D., Senior Vice President and Chief Medical Officer PR Newswire Seasoned healthcare executive and oncologist joins Executive Leadership Team SECAUCUS, N.J. , Dec. 20, 2023 /PRNewswire/ -- Quest Diagnostics (NYSE: D...

Quest Diagnostics Launches New 88-Compound Novel Psychoactive Substance Test Panel PR Newswire Xylazine found in 1 in 12 specimens tested, finds new 'Drug Misuse in America' Health Trends® report on the rising polysubstance crisis SECAUCUS, N.J. , Dec. 19, 2...

Haystack Oncology and Rutgers Cancer Institute Collaborate to use Haystack MRD™ in Clinical Study of Early-Stage Triple-Negative Breast Cancer PR Newswire BALTIMORE , Dec. 14, 2023 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company,...

NORTHAMPTON, MA / ACCESSWIRE / December 13, 2023 / Quest Diagnostics Originally published in Quest Diagnostics Corporate Responsibility Report 2022 2025/2026 Goals Implement a waste-to-energy strategy to divert from landfills' waste from several of our laboratory locations by 2025 Reduc...